As of Nov 19, 2026, 1 of 1 active firms rate ACIU a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ACIU EPS & revenue forecast
EPS · NEXT QUARTER
$0.05
Range $0.05 – $0.05 · 1 analysts · -133% YoY
Next period, 1 analysts expect AC Immune Ltd to earn $0.05 a share (range $0.05 – $0.05), versus $-0.15 a year earlier. Full-year consensus is $-0.34, growing to $0.57 the year after.
REVENUE · NEXT QUARTER
$11.8M
Range $0 – $23.6M · 1 analysts · +956% YoY
Revenue is expected to reach $11.8M (range $0 – $23.6M), +956.2% year-over-year. Full-year consensus is $22.0M, rising to $95.9M next year.
Top analysts covering AC Immune Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ACIU.
#1
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$12.00+471.4% to target
Overall win rate
45%
+ Follow
#2
Marc Goodman
Leerink Partners · Rank #251
Buy
No targeton ACIU
Overall win rate
46%
+ Follow
#3
Thomas Shrader
BTIG · Rank #553
Buy
$8.00+281.0% to target
Overall win rate
32%
+ Follow
ACIU stock forecast FAQ
What is ACIU's average 12-month price target?+
The 1 active firms with a live target average $8.00 for AC Immune Ltd over the next 12 months, ranging from a $8.00 high to a $8.00 low, as of Nov 19, 2026.
Is ACIU stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover ACIU?+
1 active firms have a recognized rating on AC Immune Ltd as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ACIU?+
Among analysts who currently cover ACIU, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #73). Their current call is Buy with a $12.00 target.
What is AC Immune Ltd's projected EPS for next quarter?+
The consensus estimate is $0.05 per share (range $0.05 – $0.05) across 1 analysts. Full-year EPS is projected at $-0.34, rising to $0.57 the following year.
How much revenue is AC Immune Ltd expected to report next quarter?+
Consensus revenue is $11.8M (range $0 – $23.6M). Full-year revenue is projected at $22.0M, growing to $95.9M next year.
Have analysts been upgrading or downgrading ACIU lately?+
As of Nov 19, 2026, 1 of 1 active firms rate ACIU a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ACIU calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.